AI and late-stage therapies keep widening the cure map
The cure pipeline remains vast and active: 21,158 trials are underway, with 24 new wire signals and 11 new cure research items in the last 24 hours. The most immediate signal is operational as much as biological — Chugai is deploying Phylo’s Biomni lab AI agents across drug discovery, while late-stage clinical readouts continue to accumulate across bleeding disorders, kidney disease, and neurodegeneration. Together, they show a field that is still expanding at both ends: better tools to find candidates faster, and better evidence that some therapies are beginning to hold disease back for years. The window is still open.
In the last 24 hours, 24 new wire signals and 11 new cure research items were added, while Chugai deployed Phylo’s Biomni lab AI agents across drug discovery and multiple late-stage therapeutic updates were reported.
If AI can compress discovery and trials can keep delivering durable benefit in serious diseases, patients and developers both gain speed, clarity, and a better chance of turning biology into lasting treatment.
Watch whether the AI-to-discovery layer translates into measurable productivity gains and whether the latest phase 3 and long-duration readouts continue to show disease stabilization rather than short-lived signal.